Pasha, Mohammed Khalid <br/><br/>
Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.  [electronic resource] 

 -  Drug metabolism letters  Mar 2012 
 - 33-42 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1874-0758 
<br/><br/><label>Standard No.: </label>10.2174/187231212800229336  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Biological Availability<br/>Caco-2 Cells<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>Cytochrome P-450 Enzyme System--drug effects<br/>Dogs<br/>Female<br/>Hepatocytes--enzymology<br/>Heterocyclic Compounds, 4 or More Rings--administration & dosage<br/>Humans<br/>Inhibitory Concentration 50<br/>Janus Kinase 2--antagonists & inhibitors<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Microsomes, Liver--metabolism<br/>Rats<br/>Rats, Wistar<br/>Species Specificity<br/>Tissue Distribution<br/>fms-Like Tyrosine Kinase 3--antagonists & inhibitors